Evaluation of Piezocision Versus Injectable Platelet-rich Fibrin During Orthodontic Canine Retraction Orthodontic Canine Retraction: A Comparative Clinical Study

November 16, 2025 updated by: farouk ahmed hussein, Al-Azhar University

Evaluation of Piezocision Versus Injectable Platelet-rich Fibrin During Orthodontic Canine Retraction: A Comparative Clinical Stud

Comparison of piezocisin and injectable platelets rich fibrin during canine retraction

Study Overview

Status

Enrolling by invitation

Conditions

Intervention / Treatment

Detailed Description

Evaluation of piezocision versus injectable platelet-rich fibrin during orthodontic canine retraction: A comparative clinical study

Study Type

Interventional

Enrollment (Estimated)

16

Phase

  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Egypt
      • Cairo, Egypt
        • Alazhar University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:. An age ranges from 14-22 years. 2. Crowding or protrusion that require 1st premolars extraction, followed by symmetrical canine retractions.

3. All permanent teeth present, 3rd molars aren't considered. 4. Good oral hygiene. 5. No systemic disease and/or medication that could interfere with orthodontic tooth movement. 6. No previous orthodontic treatment. 7. No evidence of craniofacial anomalies, such as cleft lip and palate or previous history of trauma, bruxism, or parafunction. 8. No tooth size, shape, or root abnormalities visible on patient's radiographic records.

-

Exclusion Criteria:Patients diagnosed to have an indication for non-extraction approach.

2. Poor oral hygiene or periodontally compromised patient.

  • 3. Previous orthodontic treatment. 4. Any implanted assistive (e.g., pacemakers, cochlear implants, etc.). 5. Any skeletal dysplasia or craniofacial malformation. 6. Patients with root resorption, impacted canine or dental anomalies. 7. Any systemic diseases or medications that could interfere with orthodontic tooth movement.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Randomized
  • Interventional Model: Factorial Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Iprf experimental side
Injection of platelet rich fibrin
Procedure: Iprf and piezocision
Injection of iprf and piezocisin
No Intervention: iPrf control side
Experimental: Piezocisin experimental side
Flapless incision
Procedure: Iprf and piezocision
Injection of iprf and piezocisin
No Intervention: Piezocision control sode

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Rate of canine retraction
Time Frame: 4 months
4 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Al-Azhar University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

December 1, 2025

Primary Completion (Estimated)

April 1, 2026

Study Completion (Estimated)

April 20, 2026

Study Registration Dates

First Submitted

November 16, 2025

First Submitted That Met QC Criteria

November 16, 2025

First Posted (Actual)

November 20, 2025

Study Record Updates

Last Update Posted (Actual)

November 20, 2025

Last Update Submitted That Met QC Criteria

November 16, 2025

Last Verified

November 1, 2025

More Information

Terms related to this study

Other Study ID Numbers

  • 1250/5544

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe